CT-001
Acute Bleeding (Postpartum Hemorrhage, Intracranial Hemorrhage, Traumatic Brain Injury, Trauma)
Key Facts
About Coagulant Therapeutics
Coagulant Therapeutics is a private, pre-clinical stage biotech addressing the critical unmet need for pharmaceutical interventions in acute bleeding, a leading cause of preventable death. The company's core asset is CT-001, a proprietary, engineered version of recombinant Factor VIIa (rFVIIa) optimized for greater activity and improved safety. Leveraging a foundational portfolio of over 30 patents acquired from Bayer AG and Maxygen, Coagulant aims to develop first-in-class treatments for indications like postpartum hemorrhage, intracranial hemorrhage, and trauma. The company is positioned in a large, underserved market with significant clinical and commercial potential.
View full company profile